FOLH1 and prostate adenocarcinoma: Zia et al. [86] first presented SAR-bis PSMA as a molecule consisting of a macrobicyclic sarcophogine radiochelation complex and a bivalent ligand with two PSMA-targeting groups, which demonstrates selective binding to PSMA-positive LNCaP human prostate adenocarcinoma cells.